NEWRON PHARMACEUT. EO-20 (NP5) — Cash Flow Reinvestment Rate
NEWRON PHARMACEUT. EO-20 (NP5) has a Cash Flow Reinvestment Rate of 0.00x as of June 2025, reinvesting €31.00K (capex €31.00K ) from operating cash flow of €33.60 Million. Check NEWRON PHARMACEUT. EO-20 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
NEWRON PHARMACEUT. EO-20 Cash Flow Reinvestment Rate (2012–2025)
Historical reinvestment intensity for NEWRON PHARMACEUT. EO-20 across 2 annual periods. Explore NP5 operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for NEWRON PHARMACEUT. EO-20 (2012–2025)
Year-by-year capital reinvestment analysis for NEWRON PHARMACEUT. EO-20. For live market cap and broader valuation context, see NEWRON PHARMACEUT. EO-20 market cap and net worth.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.42x | €13.66 Million | €32.56 Million | €47.31K | ▲ +22119.7% |
| 2012 | 0.00x | €11.00K | €5.83 Million | €11.00K | — |